Vnitr Lek 2011, 57(3):320-324

Variability in blood pressure and arterial hypertension

J. Widimský jr.
Centrum pro hypertenzi III. interní kliniky 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

Blood pressure variability in hypertension is an independent risk factor of cardiovascular complications, especially of stroke. Antihypertensive drugs/classes with powerful antihypertensive effect and suppression of blood pressure variability might have additional impact on the cardiovascular risk in clinical practice. Current evidence suggests that calcium channel blockers (CCB) decrease blood pressure variability more than all other antihypertensive classes. Combination of CCB with ACE-inhibitors suppresses blood pressure variability more than diuretics plus beta-blockers. Within-visit blood pressure variability (measured as coeficient of standard deviation) seems to be relatively simple and strong predictor of stroke and cardiovascular events.

Keywords: arterial hypertension; blood pressure variability; stroke

Received: February 15, 2011; Published: March 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J. Variability in blood pressure and arterial hypertension. Vnitr Lek. 2011;57(3):320-324.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Widimský jr J, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Cor Vasa 2008; 50: K5-K22.
    2. Mancia G, De Backer G, Dominiczak A et al. Management of Arterial Hypertension of the European Society of Hypertension. European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Guidelines Committee. J Hypertens 2007; 25: 1105-1187. Go to original source... Go to PubMed...
    3. Lawes CMM, Vander Hoorn S, Rodgers A. International Society of Hypertension. Global burden of blood pressure-related disease, 2001. Lancet 2008; 371: 1513-1518. Go to original source... Go to PubMed...
    4. Verdecchia P, Gentile G, Angeli F et al. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens 2010; 28: 1356-1365. Go to original source... Go to PubMed...
    5. Dahlöf B, Sever PS, Poulter NE et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. Go to original source... Go to PubMed...
    6. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665. Go to original source... Go to PubMed...
    7. Kaplan NM. Kaplan's Clinical Hypertension. 9th ed. Lippincott Williams & Wilkins 2006: 1-518.
    8. Parati G, Di Rienzo M, Ulian L et al. Clinical relevance of blood pressure variability. J Hypertens 1998; 16 (Suppl): S25-S33. Go to original source...
    9. Muntner P, Shimbo D, Tonelli M et al. The Relationship Between Visit-to-Visit Variability in Systolic Blood Pressure and All-Cause Mortality in the General Population: Findings From NHANES III, 1988 to 1994. Hypertension 2011; 57: 160-166. Go to original source... Go to PubMed...
    10. Cahan A, Ben-Dov IZ, Mekler J et al. The role of blood pressure variability in misdiagnosed clinic hypertension. Hypertens Res 2011; 34: 187-192. Go to original source... Go to PubMed...
    11. Rothwell PM, Howard SC, Dolan E et al. ASCOT-BPLA and MRC Trial Investigators. Effect of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469-480. Go to original source... Go to PubMed...
    12. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-412. Go to original source... Go to PubMed...
    13. Webb AJ, Fischer U, Mehta Z et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375: 906-915. Go to original source... Go to PubMed...
    14. Jamerson K, Weber MA, Bakris GL et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428. Go to original source... Go to PubMed...
    15. Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.